Postmenopausal Osteoporosis: Emerging Research and Trials to Watch

Why Bone Loss After Menopause Is a Women's Disease First

Postmenopausal osteoporosis is not a generic aging condition. It is driven overwhelmingly by estrogen withdrawal, a biological event unique to women. When estrogen falls at menopause, osteoclast activity (bone breakdown) surges while osteoblast activity (bone building) lags, tipping the remodeling cycle sharply toward net loss.

Estrogen suppresses RANKL-mediated osteoclast recruitment. When that brake disappears, trabecular bone at the spine and wrist erodes first because it has higher metabolic turnover. Cortical bone at the hip follows more slowly but ultimately accounts for the most dangerous fractures.

The Perimenopausal Warning Window

Bone loss does not begin at the last period. The Study of Women's Health Across the Nation (SWAN) showed that trabecular bone score begins declining roughly 1 to 2 years before the final menstrual period, with accelerated cortical loss continuing for 3 to 5 years after. That window, ages roughly 45 to 55 for most women, is when prevention interventions have the greatest return. Yet most women are not screened until they are 65 per the USPSTF guideline.

Who Is at Highest Risk

Several factors compound estrogen withdrawal:

• Early menopause (before age 45), surgical or natural
• Primary ovarian insufficiency (POI)
• History of amenorrhea from eating disorders, hypothalamic dysfunction, or endurance exercise
• Glucocorticoid use exceeding 5 mg prednisone-equivalent per day for more than 3 months
• Low body weight (BMI <18.5) and low lifetime calcium intake
• Family history of hip fracture in a first-degree relative

Women with PCOS who were treated with medroxyprogesterone acetate (Depo-Provera) for extended periods also show lower bone mineral density compared with non-users, a finding relevant for anyone now entering perimenopause who used that contraceptive for years.

How Postmenopausal Osteoporosis Is Diagnosed

A DEXA T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck meets the World Health Organization definition of osteoporosis. A score between -1.0 and -2.5 is osteopenia. Numbers matter, but they are only part of the picture.

FRAX: Fracture Risk Calculation Beyond the T-Score

The FRAX tool, developed at the University of Sheffield and endorsed by the International Society for Clinical Densitometry, incorporates clinical risk factors to generate a 10-year probability of major osteoporotic fracture and hip fracture. The National Osteoporosis Foundation (NOF) and AACE recommend treatment when the 10-year hip fracture probability reaches 3% or the major fracture probability reaches 20%, even without a T-score reaching -2.5.

Trabecular Bone Score: Reading Bone Quality, Not Just Density

DEXA measures quantity. Trabecular Bone Score (TBS) measures texture at the spine, which reflects microarchitectural quality independently of density. A 2017 meta-analysis of 14 prospective cohorts showed TBS independently predicted fracture even after adjusting for DEXA T-score, with a hazard ratio of 1.44 per standard deviation decrease for major osteoporotic fracture. TBS is now incorporated into FRAX calculations at specialty centers, though it is not yet universally reimbursed.

High-Resolution Peripheral Quantitative CT (HR-pQCT)

This research-grade imaging tool, available at academic centers, scans the radius and tibia at resolutions under 100 microns. It can distinguish cortical from trabecular compartments and detect microstructural deterioration before a T-score crosses the diagnostic threshold. HR-pQCT is not standard clinical practice yet, but several ongoing trials use it as a secondary endpoint, making it a technique to follow.

Current Standard-of-Care Treatments

Before examining what is emerging, you need a clear map of what is already approved and where each drug fits in a woman's life.

Antiresorptives: Slowing Breakdown

Bisphosphonates (alendronate, risedronate, zoledronic acid, ibandronate) are the most prescribed first-line drugs worldwide. Alendronate 70 mg once weekly reduced vertebral fracture risk by 47% and hip fracture risk by 51% in the Fracture Intervention Trial (FIT). They work by binding hydroxyapatite and inducing osteoclast apoptosis.

Denosumab (Prolia) 60 mg every 6 months is a RANK-ligand inhibitor. The FREEDOM trial showed a 68% relative reduction in new vertebral fracture over 3 years versus placebo. A critical caveat: denosumab is not a drug you can stop casually. Discontinuation causes a rebound surge in bone resorption and multiple vertebral fractures within 12 to 18 months. Transition to a bisphosphonate is mandatory when stopping.

Raloxifene (Evista), a selective estrogen receptor modulator (SERM), reduces vertebral fracture risk but has not demonstrated hip fracture reduction. It has the added benefit of reducing invasive breast cancer risk by approximately 44%, making it a consideration for women at elevated breast cancer risk who also have spine-predominant low bone density.

Hormone therapy (HT) with estrogen, with or without progesterone, prevents bone loss and reduces fracture risk. The Women's Health Initiative (WHI) showed that combined estrogen-progestogen therapy reduced hip fracture by 34% and all osteoporotic fractures by 24%. The Menopause Society's 2023 position statement now explicitly states that HT is appropriate for fracture prevention in postmenopausal women under 60 or within 10 years of menopause who also have vasomotor symptoms, making it a rare drug that addresses two problems simultaneously.

Anabolics: Building Bone

Teriparatide (Forteo) and abaloparatide (Tymlos) are PTH-axis drugs that stimulate osteoblasts directly. Teriparatide 20 mcg daily reduced new vertebral fractures by 65% in a key RCT published in the NEJM. Both are limited to 2 years of use due to a historical osteosarcoma signal in rats, though that signal has not materialized in humans after two-plus decades of use. After stopping, an antiresorptive must follow to preserve gains.

Romosozumab: The Dual-Action Drug Changing the Treatment Ceiling

Romosozumab (Evenity) is the most significant addition to osteoporosis pharmacology since denosumab. It works by inhibiting sclerostin, a protein produced by osteocytes that normally restrains bone formation. Blocking it simultaneously increases bone formation and decreases bone resorption, a mechanism no prior drug achieved.

The ARCH trial compared romosozumab 210 mg monthly for 12 months followed by alendronate against alendronate alone in 4,093 postmenopausal women with osteoporosis and prior fracture. The romosozumab-to-alendronate sequence cut new vertebral fracture risk by 48% and hip fracture by 38% versus alendronate alone. That is a clinically important difference: no sequential therapy previously showed that magnitude of hip fracture reduction over an alendronate comparator.

The Cardiovascular Caveat

The ARCH trial showed a slightly higher rate of serious cardiovascular events in the romosozumab arm (2.5% vs. 1.9%). The FDA responded with a boxed warning. Romosozumab is contraindicated in women who have had a myocardial infarction or stroke within the past year. For the high-risk fracture patient without recent cardiovascular events, the bone benefit may substantially outweigh the risk, but this is a real, individualized conversation you need to have with your prescriber.

Life-Stage Fit for Romosozumab

Romosozumab is approved only for postmenopausal women. It is not studied in premenopausal women, women with POI, or those with glucocorticoid-induced osteoporosis. The label specifies the population clearly: postmenopausal women at high risk for fracture, defined as prior fracture, multiple risk factors, or inadequate response to other therapy.

Emerging Research: Trials and Agents to Watch in 2024 and Beyond

The pipeline for postmenopausal osteoporosis is more active than at any point in the last decade. Below is a structured framework for thinking about which innovations are closest to practice-change versus years away.

Tier 1: Evidence Already Changing Practice

Romosozumab followed by denosumab. The FRAME trial tested romosozumab versus placebo, then both groups transitioned to denosumab. The FRAME extension at 24 months showed that the romosozumab-to-denosumab sequence produced greater total BMD gains than placebo-to-denosumab, and those gains were maintained at 48 months. Sequencing anabolic therapy before antiresorptive therapy is now endorsed by the AACE/ACE 2020 clinical practice guidelines for severe osteoporosis.

Abaloparatide-to-alendronate. The ACTIVExtend study followed the ACTIVE trial participants who had received abaloparatide for 18 months into a 24-month extension on alendronate. At the end of ACTIVExtend, vertebral fracture risk reduction was 84% compared with the placebo-alendronate arm. This confirms that the anabolic-then-antiresorptive strategy is broadly applicable, not specific to one drug.

Tier 2: Phase 2 and Phase 3 Trials Actively Enrolling

Setrusumab (BPS804). This anti-sclerostin monoclonal antibody is in Phase 3 for osteogenesis imperfecta, but Phase 2 data in postmenopausal osteoporosis showed bone turnover marker changes consistent with anabolic activity. Setrusumab targets a different epitope on sclerostin than romosozumab. Whether that translates into a different cardiovascular profile is the central question researchers are trying to answer.

Odanacatib (cathepsin K inhibitor). Odanacatib had a Phase 3 trial (LOFT) showing 54% vertebral fracture reduction and was actually submitted to the FDA, but Merck voluntarily withdrew the application in 2016 after a post-hoc analysis found increased stroke risk. Several academic groups are revisiting the mechanism with next-generation cathepsin K inhibitors using different selectivity profiles. Nothing is near approval, but the mechanism remains scientifically compelling.

Parathyroid hormone-related protein (PTHrP) analogs. Abaloparatide is a PTHrP analog already approved, but several investigational analogs with longer half-lives are in early trials, aiming to reduce injection frequency from daily to weekly.

Emerging Diagnostic Technology

Opportunistic CT screening. Abdominal CT scans performed for other reasons contain Hounsfield unit data at the lumbar vertebrae. A 2022 study in JAMA Internal Medicine showed that automated analysis of opportunistic CT could identify women with osteoporosis-level bone density who had never been formally screened, with high sensitivity and specificity. This approach could dramatically reduce the rate of undiagnosed osteoporosis, which remains high: only about 23% of women with osteoporosis in the U.S. Are currently treated.

Bone turnover markers as treatment monitoring tools. Serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide) are resorption and formation markers that respond to therapy within weeks. The Endocrine Society's 2019 clinical practice guideline acknowledges these markers as useful for confirming therapeutic response between DEXA scans, particularly for women on anabolic therapy where BMD changes may lag behind actual bone quality improvements.

Genetic and Precision Medicine Approaches

Genome-wide association studies (GWAS) have identified over 1,100 genetic loci associated with BMD. Two loci in the LRP5 and RANKL pathways are already represented in approved drugs (denosumab targets RANKL; the sclerostin pathway intersects LRP5/Wnt signaling). Research groups are mapping polygenic risk scores for fracture that may one day allow identification of women in their 30s and 40s who need early intervention before perimenopausal bone loss begins. This is 5 to 10 years from clinical use, but it represents the direction the field is heading.

Sex-Specific Pharmacokinetics and Dosing Differences

Women metabolize several osteoporosis drugs differently than men, though this is rarely discussed in standard clinical summaries.

Bisphosphonates are cleared renally. Women have lower average glomerular filtration rates (GFR) at equivalent ages, partly due to lower muscle mass and lower creatinine generation. Zoledronic acid 5 mg IV is not recommended when creatinine clearance falls below 35 mL/min, and GFR declines faster postmenopause than in men of the same age. Your kidney function is worth checking before each annual or biannual dose.

Body weight influences teriparatide exposure. Lower body weight, common in thin postmenopausal women who are already at higher fracture risk, produces higher peak concentrations after the standard 20 mcg dose. While no dose adjustment is currently recommended, nausea and dizziness are more likely at higher exposure levels. Injecting in the evening and lying down afterward reduces these side effects for most women.

Pregnancy and Lactation: What Every Woman Must Know

This section is not relevant for the primary postmenopausal population but is mandatory for women who develop osteoporosis during reproductive years, including those with pregnancy-associated osteoporosis (PAO) or glucocorticoid-induced osteoporosis treated during reproductive life.

Bisphosphonates

Bisphosphonates are classified FDA Pregnancy Category C (older system) or have limited human data under the current Pregnancy and Lactation Labeling Rule (PLLR). Animal data shows fetal harm at high doses. Bisphosphonates bind to fetal bone because they cross the placenta and incorporate into developing skeletal tissue. There is no established safe exposure in pregnancy. Women who become pregnant while on bisphosphonate therapy should contact their prescriber immediately, though observational data suggests accidental first-trimester exposure does not appear to cause consistent fetal harm.

Because bisphosphonates remain in bone for years to decades, the theoretical concern about fetal bone exposure exists even if you stop the drug before conception. For young women with osteoporosis who may become pregnant, this is a real shared-decision conversation.

Denosumab

Denosumab is contraindicated in pregnancy. RANKL is essential for lymph node formation and immune development in the fetus. Animal studies show dose-dependent absence of lymph nodes and fetal harm. Women of reproductive potential must use effective contraception during treatment and for at least 5 months after the last dose.

Romosozumab

Romosozumab is contraindicated in pregnancy. Sclerostin plays a role in fetal skeletal development; animal data shows fetal abnormalities at subclinical doses. Effective contraception is required during treatment.

Teriparatide and Abaloparatide

Both are contraindicated in pregnancy. Animal studies show skeletal abnormalities. Neither has been studied in lactating women, and their large molecular size suggests limited transfer to breast milk, but this has not been formally evaluated.

Pregnancy-Associated Osteoporosis (PAO)

PAO is rare but real. It typically presents as severe vertebral fractures in the third trimester or early postpartum, when calcium demand from fetal skeletal mineralization and lactation temporarily exceeds maternal supply. Case series and registry data suggest an incidence of roughly 4 to 8 per million pregnancies. Management during active pregnancy is largely supportive (calcium, vitamin D, mobility modification). Most women are treated with bisphosphonates or teriparatide after delivery, once breastfeeding is complete. The evidence base for PAO treatment is almost entirely observational; women have historically been excluded from the RCTs that define standard care, a gap the field has not adequately addressed.

Who This Is Right For and Who Should Pause

Most Likely to Benefit From Evaluation Now

You are in the highest priority group for a DEXA scan and fracture risk assessment if you are:

• Postmenopausal, any age, with a low-trauma fracture after age 50
• Age 65 or older, per USPSTF recommendation
• Postmenopausal and under 65 with any major risk factor (family history of hip fracture, BMI <20, smoking, glucocorticoid use, prior fracture)
• In the AACE-defined "very high risk" category: T-score <-3.0, or any hip or vertebral fracture, or FRAX 10-year major fracture probability above 30%

For very high risk women, current guidelines support starting with an anabolic agent (romosozumab, teriparatide, or abaloparatide) before antiresorptive therapy, not the reverse.

Who Should Not Use Specific Drugs

• Romosozumab: avoid if you have had MI or stroke within the past year; not studied premenopausally
• Denosumab: avoid in pregnancy, in hypocalcemia (correct calcium before starting), and in anyone who cannot commit to continuation or structured transition
• Bisphosphonates: avoid if creatinine clearance is <30-35 mL/min; use with caution in women with Barrett's esophagus (oral forms)
• Raloxifene: contraindicated in women with personal or family history of DVT or pulmonary embolism; increases VTE risk roughly 3-fold
• Teriparatide and abaloparatide: avoid in anyone with prior radiation to the skeleton, Paget's disease, unexplained elevated alkaline phosphatase, or bone metastases

What to Ask Your Clinician at Your Next Visit

These are the specific questions that will move your care forward, not generic prompts:

1. "My last DEXA was [X years ago]. Given that I am [X years postmenopausal], when should I repeat it and should TBS be added?"
2. "Have you run a FRAX calculation for me? What is my 10-year major fracture probability?"
3. "Am I in the AACE very-high-risk category? If yes, should I be starting with an anabolic drug rather than a bisphosphonate?"
4. "If I start denosumab, what is the transition plan when I eventually stop?"
5. "I have [PCOS / early menopause / history of Depo-Provera use]. Does that change my baseline risk?"